Gujarat Kidney and Super Speciality Limited (GKSL)
Market Closed
10 Aug, 22:00
MSE MSE Primary XNSE ₹
133. 30
-1.1
-0.8184%
₹
10.34B Market Cap
- P/E Ratio
- Div Yield
18,254 Volume
- Eps
₹ 134.4
Previous Close Want to track GKSL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
GKSL closed today lower at ₹133.3, a decrease of -0.8184% from yesterday's close, completing a monthly increase of 4.7133% or ₹6. Over the past 12 months, GKSL stock gained 28.3582%.
GKSL is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on MSE (INR).
GKSL Chart
Gujarat Kidney and Super Speciality Limited (GKSL) FAQ
What is the stock price today?
The current price is ₹133.30.
On which exchange is it traded?
Gujarat Kidney and Super Speciality Limited is listed on MSE.
What is its stock symbol?
The ticker symbol is GKSL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 10.34B.
Has Gujarat Kidney and Super Speciality Limited ever had a stock split?
No, there has never been a stock split.
Gujarat Kidney and Super Speciality Limited Profile
| - Industry | - Sector | - CEO | MSE Exchange | - ISIN |
| India Country | 354 Employees | - Last Dividend | - Last Split | - IPO Date |
Gujarat Kidney and Super Speciality Limited is a regional multispecialty hospital chain focused on secondary and tertiary care services in central Gujarat, India. Headquartered in Vadodara and founded in 2019, the company operates six hospitals across four cities, offering integrated end-to-end patient care through in-house diagnostics and pharmacies. It specializes in renal sciences, urology subspecialties, vascular surgery, gynecology, obstetrics, robotic, bariatric, laparoscopic, endocrine, neurosurgery, joint replacement, and interventional cardiology. Employing an asset-light model on leased premises, Gujarat Kidney and Super Speciality Limited pursues inorganic growth via acquisitions like Parekhs Hospital and Ashwini Medical Centre, enabling rapid scaling with minimal capital outlay. Key strengths include pre-eminence in renal care, low doctor and nurse attrition, centralized procurement for efficiency, and a focus on underpenetrated markets. Financially, it reported revenue of INR 47.74 million in 2024, with consistent EBITDA positivity and rising profitability, supported by experienced leadership and strategic bed expansion to 539 approved beds.
Contact Information
Address: Plot No. 1
Phone: 91 26 5298 4800
